ATAI Life Sciences N.V. Common Shares
Symbol: ATAI (NASDAQ)
4.76
▼ (-2.66%) -0.130
Company Description:
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Key Stats
- Today's Open: $4.915
- Today's High: $4.985
- Today's Low: $4.635
- Today's Volume: 4.80M
- Yesterday Close: $4.89
- Yesterday High: $4.89
- Yesterday Low: $4.4542
- Yesterday Volume: 5.06M
- Last Min Volume: 27
- Last Min High: $4.76
- Last Min Low: $4.76
- Last Min VWAP: $4.76
Company Profile
- Name: ATAI Life Sciences N.V. Common Shares
- Website: https://www.atai.life
- Listed Date: 2021-06-18
- Location: AMSTELVEEN,
- Market Status: Active
- CIK Number: 0001840904
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $968.81M
- Round Lot: 100
- Outstanding Shares: 214.34M
- Asset Type: CS
RECENT FILINGS FOR ATAI
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-18 | SCHEDULE 13D/A | View |
| 2025-08-18 | 4 | View |
| 2025-08-15 | 4 | View |
| 2025-08-14 | 10-Q | View |
| 2025-08-14 | DEFA14A | View |
| 2025-08-14 | 8-K | View |
| 2025-07-02 | 144 | View |
| 2025-07-02 | DEFA14A | View |
| 2025-07-02 | DEFA14A | View |
| 2025-07-01 | 144 | View |
| 2025-07-01 | 8-K | View |
| 2025-07-01 | DEFA14A | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-18 | DEFA14A | View |
Latest News on ATAI